In a groundbreaking initiative, the National Diabetes Association Ghana has announced the distribution of 300 boxes of ...

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Sales of Merck's new drug, Winrevair, more than doubled sequentially in the third quarter. The news could bolster downtrodden Merck stock.

Sitagliptin (Januvia; Merck), the only marketed DPP4 inhibitor, was approved in October 2006. As a monotherapy, sitagliptin dosed daily achieved HbA1c reductions similar to those seen with the ...

From drug pricing to reforming the drug regulatory process, Trump’s re-election has plenty of implications for the pharma ...

CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a ...

CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company') (NASDAQ:COSM), a ...

The pharmaceutical giant’s key U.S. intellectual property on the active ingredient in Januvia was set to expire in early 2023 ...

Dow has been struggling to grow for several quarters. Keytruda now makes up close to half of Merck's revenue. As you can see ...

Darwin’s great achievement was to show how natural selection could fashion unimaginable biological complexity and adaptive functionality, without the need for a creative designer. Today, Codexis ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...